CN104010664A - 用于治疗多发性硬化的apc介导的耐受诱导 - Google Patents

用于治疗多发性硬化的apc介导的耐受诱导 Download PDF

Info

Publication number
CN104010664A
CN104010664A CN201280058005.9A CN201280058005A CN104010664A CN 104010664 A CN104010664 A CN 104010664A CN 201280058005 A CN201280058005 A CN 201280058005A CN 104010664 A CN104010664 A CN 104010664A
Authority
CN
China
Prior art keywords
cell
dendritic cell
multiple sclerosis
mog
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280058005.9A
Other languages
English (en)
Chinese (zh)
Inventor
C·德雷施
B·戴安德雷德佩雷拉
M·阿克曼
C·法拉艾费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of CN104010664A publication Critical patent/CN104010664A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280058005.9A 2011-09-26 2012-09-26 用于治疗多发性硬化的apc介导的耐受诱导 Pending CN104010664A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11182700.2 2011-09-26
EP11182700 2011-09-26
US61/573,200 2011-11-14
PCT/EP2012/068954 WO2013045488A1 (en) 2011-09-26 2012-09-26 Apc-mediated tolerance induction for therapy of multiple sclerosis

Publications (1)

Publication Number Publication Date
CN104010664A true CN104010664A (zh) 2014-08-27

Family

ID=46924448

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280058005.9A Pending CN104010664A (zh) 2011-09-26 2012-09-26 用于治疗多发性硬化的apc介导的耐受诱导

Country Status (6)

Country Link
US (1) US9592259B2 (enExample)
EP (1) EP2760478A1 (enExample)
JP (1) JP2015502135A (enExample)
KR (1) KR20140116054A (enExample)
CN (1) CN104010664A (enExample)
WO (1) WO2013045488A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111089972A (zh) * 2019-12-18 2020-05-01 天津天海新域生物科技有限公司 一种用于检测抗人体髓鞘碱性蛋白抗体的试剂盒及其应用
CN116200414A (zh) * 2022-08-31 2023-06-02 天津华科泰生物技术有限公司 一种重组人髓鞘少突胶质细胞糖蛋白及其制备方法和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3013362B1 (en) 2013-06-28 2021-08-04 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
DK3133923T3 (da) * 2014-04-24 2020-08-10 Univ Florida Aav-based gene therapy for multiple sclerosis
US12485186B2 (en) 2017-03-31 2025-12-02 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
AU2020289326A1 (en) * 2019-06-04 2022-01-27 Thomas Jefferson University Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis
EP4135777A4 (en) 2020-04-14 2025-03-12 University Of Florida Research Foundation, Incorporated AAV-BASED GENE THERAPIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
WO2023240274A1 (en) * 2022-06-10 2023-12-14 The Medical College Of Wisconsin, Inc. Immune tolerance induction for auto-immune diseases through platelet targeted gene therapy involving myelin oligodendrocyte glycoprotein (mog) polypeptide.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047465A1 (en) * 2005-10-13 2007-04-26 Anthrogenesis Corporation Production of oligodendrocytes from placenta-derived stem cells
CN1993143A (zh) * 2004-06-04 2007-07-04 健泰科生物技术公司 用于治疗多发性硬化的方法
WO2009024348A1 (de) * 2007-08-21 2009-02-26 Imtm Gmbh Verfahren zur aktivierung regulatorischer t-zellen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090982B2 (en) * 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
IL141813A (en) * 2001-03-05 2010-04-15 Hadasit Med Res Service Mixture comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the preparation of compositions for the treatment of hematopoietic dusirders
US20030049797A1 (en) * 2001-04-16 2003-03-13 Yoshikazu Yuki Hybrid proteins for autoimmune disease
JP5010220B2 (ja) * 2006-09-11 2012-08-29 三菱化学メディエンス株式会社 造血幹細胞移植療法の施行患者の病態把握方法
US8188218B2 (en) * 2006-10-27 2012-05-29 University Of Kansas Bi-functional peptides for multiple sclerosis treatment and diagnosis
US8673286B2 (en) 2007-04-09 2014-03-18 Northwestern University DOPA-functionalized, branched, poly(aklylene oxide) adhesives
KR101103423B1 (ko) 2009-09-04 2012-01-06 아주대학교산학협력단 생체 주입형 조직 접착성 하이드로젤 및 이의 생의학적 용도
US20130053594A1 (en) 2009-12-17 2013-02-28 The University Of Chicago Methods of making self-healing polymer and gel compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993143A (zh) * 2004-06-04 2007-07-04 健泰科生物技术公司 用于治疗多发性硬化的方法
WO2007047465A1 (en) * 2005-10-13 2007-04-26 Anthrogenesis Corporation Production of oligodendrocytes from placenta-derived stem cells
WO2009024348A1 (de) * 2007-08-21 2009-02-26 Imtm Gmbh Verfahren zur aktivierung regulatorischer t-zellen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRESCH.C ET AL: "LENTIVIRAL-MEDIATED TRANSCRIPTIONAL TARGETING OF DENDRITIC CELLS FOR INDUCTION OF T CELL TOLERANCE IN VIVO", 《THE JOURNAL OF IMMUNOLOGY》 *
HARTGERS FRANCA C ET AL: "DC-STAMP，a novel multimembrane spanning molecule preferentially expressed by dendritic cells", 《EUR J IMMUNOL》 *
KO HYUN-JA ET AL: "Targeting MOG expression to dendritic cells delays of onset of experimental autoimmune disease", 《AUTOIMMUNITY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111089972A (zh) * 2019-12-18 2020-05-01 天津天海新域生物科技有限公司 一种用于检测抗人体髓鞘碱性蛋白抗体的试剂盒及其应用
CN111089972B (zh) * 2019-12-18 2021-05-14 天津天海新域生物科技有限公司 一种用于检测抗人体髓鞘碱性蛋白抗体的试剂盒及其应用
CN116200414A (zh) * 2022-08-31 2023-06-02 天津华科泰生物技术有限公司 一种重组人髓鞘少突胶质细胞糖蛋白及其制备方法和应用

Also Published As

Publication number Publication date
US9592259B2 (en) 2017-03-14
JP2015502135A (ja) 2015-01-22
US20140242037A1 (en) 2014-08-28
KR20140116054A (ko) 2014-10-01
WO2013045488A1 (en) 2013-04-04
EP2760478A1 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
CN104010664A (zh) 用于治疗多发性硬化的apc介导的耐受诱导
US9018006B2 (en) Stable Tregs and related materials and methods
US20080311140A1 (en) Antigen specific immunosuppression by dendritic cell therapy
JP2022065022A (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
JP5898260B2 (ja) 併用療法におけるｃｄ８３の使用
Arce et al. Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen‐specific regulatory T cells, and suppresses experimental inflammatory arthritis
ES2895901T3 (es) Células T transducidas con CXCR6 para terapia tumoral dirigida
CN108159407A (zh) 用于治疗关节炎病的组合物
Koga et al. IL10-and IL35-secreting MutuDC lines act in cooperation to inhibit memory T cell activation through LAG-3 expression
KR20170101147A (ko) 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물
Ahangarani et al. In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL-10-dependent antigen-specific unresponsiveness
Saha et al. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen
Sicard et al. Cell therapy to induce allograft tolerance: time to switch to plan B?
US9315558B2 (en) Use of interleukin 10 mRNA transfected macrophages in anti-inflammatory therapies
JP2025069165A (ja) 耐性を誘導するための操作された細胞
EP1589030A1 (en) Bob-1 specific T cells and methods to use
WO2017214190A1 (en) Engineered dendritic cells that express 1a-hydroxylase and uses thereof for treating immune-mediated diseases
Horn et al. Gene therapy in the transplantation of allogeneic organs and stem cells
EP4285913A1 (en) Highly effective adoptive t cell therapy
EP3958887B1 (en) Medical uses for inducing or restoring immune tolerance
Dejin Tailored Engineering of NK-Resistant Mesenchymal Stromal Cells
JP2017533238A (ja) 抗原特異的寛容のための組成物及び方法
Janssens Induction of Tolerance by Genetically-Engineered B Cells and Cytotoxic T Cells in Allergic Diseases
Li CD24 in T lymphocyte homeostatic proliferation and autoimmune disease
MacDonald Understanding & optimizing human T regulatory cell function in patients with autoimmunity and/or undergoing transplantation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140827